Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT02242084 Terminated - Clinical trials for Motor Weakness in Two or Four Limbs

Thrombolysis in Ischemic Spinal Cord Stroke

Start date: April 2016
Phase: Phase 2
Study type: Interventional

Ischemic stroke of the spinal cord is a rare disease accounting for about 1% of all ischemic events in the central nervous system (CNS). In most cases the consequences are catastrophic, with a high rate of severe functional disability and mortality rate up to 30%. Ischemic stroke of the spinal cord can arise from: 1. Dissection of the aorta. 2. Aneurism in the aorta. 3. Atherosclerotic disease of the aorta or vertebral arteries. 4. Spinal surgeries. 5. Spinal AVM. 6. Embolism from cardiac origin. 7. Occlusion of radicular artery. Onset is usually sudden, reaching maximal intensity in hours until the patient becomes paralyzed in two or in all four limbs. In most cases the damage is in the Anterior Spinal Artery (ASA). The disease is expressed with motor weakness accompanied by disturbance of temperature and superficial sensation, urinary retention or bowel disorder, with preserved position and vibration sense. The differential diagnosis of ischemic spinal cord includes diseases such as acute myelitis of the spinal cord or acute demyelinating polyneuropathy like Guillan Barree Syndrome (GBS). Therefore in order to reach the appropriate diagnosis in most cases an urgent MRI of the spinal cord is necessary upon arrival in the emergency department. One of the treatments to acute ischemic stroke is providing thrombolysis. As tested and validated in numerous studies for ischemic events in the brain, until today no validated study in ischemic spinal stroke using thrombolysis has been completed.

NCT ID: NCT02241551 Terminated - Clinical trials for Borderline Resectable Pancreatic Cancer

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

NCT ID: NCT02240758 Terminated - Clinical trials for Low Grade Glioma (LGG), High Grade Glioma (HGG)

Confocal Laser Endomicroscopy for Brain Tumors

GLIOFOCAL
Start date: September 2014
Phase: Phase 1
Study type: Interventional

Confocal Laser Endomicroscopy (CLE) could be a useful tool for real-time diagnosis of brain lesions (initial diagnosis or follow-up post resection to check for residual dysplasia) and real-time assessment of resections margins during surgery. Probe-based CLE using the CELLVIZIO® has never been used for glioma surgical guided resection. Before assessing the potential of this technique in improving surgical resection outcome, a feasability study has to be performed.

NCT ID: NCT02239926 Terminated - Clinical trials for Diarrhea Predominant Irritable Bowel Syndrome

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

Ranolazine
Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?

NCT ID: NCT02238938 Terminated - Clinical trials for Colorectal Adenomatous Polyp

Piecemeal Versus En Bloc Resection of Large Rectal Adenomas

PERLA
Start date: April 2014
Phase: N/A
Study type: Interventional

Currently, colonoscopy is the safest way to detect bowel tumors and polyps, since these can be biopsied and removed in one working process. If the size of adenomas is larger than 2 cm, resections are usually done in a hospital setting. For the resection of large adenomas, different approaches can be used. The so-called piecemeal resection is done with snares, to cut off parts of the adenoma piece by piece until the whole adenoma is resected. This technique is the standard therapy, but is not required for very large adenomas, which can often show cell alterations that indicate cancer. Therefore these adenomas should be resected in one piece. This is done by the so-called en-bloc resection. For this kind of therapy, different endoscopic knifes are use to cut off the adenoma as a whole. Both resection techniques are done usually by previous injection of saline or other liquids to elevate the lesion from its bottom tissue. Although the piecemeal resection of large adenoma is the standard therapy, it shows recurrence rates of 10 to 25%, which afford repeated therapies and follow up controls. En-bloc resections, though, are expected to have less recurrence rates but are much more complex to perform. They have higher complication rates especially in the West, where it has bee introduced only a couple of years ago. The data situation regarding safety and efficacy of both therapies is low. This study is the first one ever to compare piecemeal EMR and ESD in a randomized way. The study might have influence on the logistics of future adenoma processing and patient flow.

NCT ID: NCT02237703 Terminated - Trauma Clinical Trials

Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Start date: March 2012
Phase: N/A
Study type: Observational

This study uses positron emission tomography (PET) imaging to measure kappa opioid receptors (KOR) in the brains of individuals with and without post-traumatic stress disorder (PTSD). The investigators propose to recruit 45 drug-naïve individuals, N=15 patients with PTSD, N=15 trauma-exposed, but asymptomatic healthy control subjects (TC) and N=15 non-trauma exposed healthy control subjects (HC) to participate in one magnetic resonance imaging (MRI) and one PET study. The investigators will also carefully document trauma history, and collect behavioral and neuroendocrine measures to provide a more integrative view on the neurobiology of PTSD and its phenotype. The investigators predict PTSD will show greater carbon - 11 (11C)[11C]LY2795050 volume of distribution (VT) (i.e. KOR binding) values than control populations in an a priori defined PTSD circuit.

NCT ID: NCT02237677 Terminated - Clinical trials for Post-traumatic Stress Disorder (PTSD)

CB1 Receptor PET Imaging Reveals Gender Differences in PTSD

Start date: June 2012
Phase: N/A
Study type: Observational

The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.

NCT ID: NCT02236936 Terminated - Clinical trials for Locally Advanced Malignant Neoplasm

Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

AGMT_HNO_PN
Start date: February 3, 2017
Phase: Phase 3
Study type: Interventional

Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result in higher treatment related toxicity and discontinuation of a potential curative treatment. Thus the investigators want to evaluate the efficacy of overnight parenteral nutritional (PN) support in patients with SCCHN treated with curative radiotherapy (RTX) in combination with Cetuximab (E) or Cisplatin (P).

NCT ID: NCT02236130 Terminated - Clinical trials for Pediatric Extremity Soft Tissue Injury

Peripheral Nerve Blocks in Pediatric Orthopedic Patients

Start date: June 2014
Phase: N/A
Study type: Interventional

Context: Single shot peripheral nerve blocks have limited duration of action depending on the local anesthetic agent used in the block. But it rarely lasts longer than 12 hrs. Patients need oral analgesics at home once the block wears off to control the pain. Objectives: Primary Objective To determine if peripheral nerve blocks have any advantage in terms of decreasing oral analgesic requirements in the post operative period even after the effects of the block have worn off Secondary Objective To determine if inclusion of single shot regional technique improves patient/family satisfaction with post operative pain management . Study Design: Prospective randomized single blinded study. Inclusion Criteria - Children aged between 6 yr and 17yr scheduled for ambulatory peripheral orthopedic surgery with moderate to severe postoperative pain. - Surgery of moderate duration (<2hr) - Surgery associated with minimal blood loss or fluid shifts (<10% total blood volume) - American Society of Anesthesiologists (ASA) classification 1 or 2 - Parents able to understand follow up instructions and are able to reach at home by phone Exclusion Criteria - Known allergy to local anesthetics - Preexisting neuropathy with sensory or motor deficits - Skin infection at site of needle placement - Parents refusal for peripheral nerve blocks

NCT ID: NCT02235441 Terminated - Clinical trials for Plan of Care Must Include Chemoradiation

Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies

Start date: November 2014
Phase: N/A
Study type: Interventional

There is growing evidence of the integral role of exercise following cancer treatment. Randomized trials show that exercise improves post treatment symptoms and quality of life in breast and prostate cancer patients.Regular exercise reduces cancer specific and all cause mortality for patients with breast, prostate, brain or colorectal cancer. Nearly a 40-50% relative risk reduction in cancer specific death and 20-50% relative risk reduction in all cause mortality have been reported with exercise. At present it is unknown if preclinical pleiotropic effects on tumors through aerobic exercise are clinically relevant. Before launching into further studies of exercise training on changes in tumor hypoxia and response to CRT in rectal cancer patients, it is first important to understand: 1. Whether measures of exercise exposure (i.e., exercise capacity and self-reported exercise behavior) are associated with markers of tumor hypoxia at diagnosis (prior to initiation of CRT) and 2. Whether changes in measures of exercise exposure over the course of CRT are related to changes in tumor hypoxia and response to CRT.